Extrawell Pharmaceutical Holdings Limited provided consolidated earnings guidance for the year ended March 31, 2022. For the year, the company expected to record an increase in profit of about HKD 260 million which was primarily attributable to a non-cash item, resulted from an increase in a gain of about HKD 169 million arising from the fair value change of the Group's investments in convertible bonds, as compared to a loss for the year ended March 31, 2021 which was incurred primarily due to the fair value change (loss) of the same item.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.039 HKD | +5.41% | +2.63% | +14.71% |
2023 | Extrawell Pharmaceutical Swings to Fiscal H1 Loss on Fair Value Losses | MT |
2023 | Extrawell Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended September 30, 2023 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+14.71% | 11.92M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- 858 Stock
- News Extrawell Pharmaceutical Holdings Limited
- Extrawell Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended March 31, 2022